ImmunityBio (IBRX) reported a Q1 net loss Monday of $0.15 per diluted share, narrowing from a loss of $0.20 a year earlier.
Analysts polled by FactSet expected a loss of $0.13.
Revenue for the quarter ended March 31 was $16.5 million, up from $40,000 a year earlier.
Analysts surveyed by FactSet expected $16 million.
Shares of the company were up 2.4% in recent premarket activity.